Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04260997
Other study ID # AFCRO-112
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 1, 2020
Est. completion date September 1, 2021

Study information

Verified date September 2021
Source UAS Labs LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Lactobacillus gasseri BNR17™ has shown promise in several pre-clinical and randomized controlled clinical trials for weight management outcomes. The current randomized, double-blind, placebo-controlled, parallel-arm trial will further assess L. gasseri BNR17™ on body composition and weight management, and in a study population that is distinct to prior randomized controlled trials on the strain. The study will recruit 126 overweight adult participants who will be randomly assigned to consume L. gasseri BNR17™ or placebo once daily for 12 weeks.


Recruitment information / eligibility

Status Completed
Enrollment 125
Est. completion date September 1, 2021
Est. primary completion date May 1, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 25 Years to 65 Years
Eligibility Inclusion Criteria: - Written informed consent; - Aged between 25 and 65 years inclusive; - Body mass index between 25.0 to 29.9 Kg/m2, inclusive; - Waist-hip ratio of =0.91 for males and =0.81 for females; - Sedentary lifestyle, exercising =2 times/week; - Good general health, as determined by the investigator; - Willing to consume the investigational product daily for the duration of the study; - Outside the healthy parameters of visceral adipose tissue, defined as 762 cm3 for males and 256 cm3 for females. Exclusion Criteria: - Females who are pregnant, lactating or wish to become pregnant during the study; - Participant regularly takes probiotic supplements, or has within the 4-weeks prior to randomisation or plans to during the study; - Participant is hypersensitive to any of the components of the investigational product; - Participant is severely immuno-compromised (HIV positive, transplant patient, on antirejection medications, on a steroid for >30 days, or has underwent chemotherapy or radiotherapy within the last year); - Participant has Type 1 or Type 2 Diabetes Mellitus; - Participant has a history of bariatric surgery; - Participant has taken anti-obesity medication or supplements in the 12-weeks prior to randomisation or plans to during the study; - Participant is actively or has recently (3 months prior to randomisation) participated in a weight loss program or weight change of 3 kg during the past 3 months; - Participant has a life-threatening illness; - Participant is on a glucose lowering medication, anti-psychotic drugs or any medication that the investigator determines could impact the results of the study; participant has commenced use, within 3-months of randomisation, anti-hypertensive drugs, anti-depressive drugs, statin or any other medication that the investigator determines could impact the results of the study; - Participant has a history of co-existing gastrointestinal, and/or gynecological, and/or urologic pathology (e.g. colon cancer, colitis, Crohn's Disease, Celiac, Endometriosis, prostate cancer) or lactose intolerance; - Participant has a recent history of drug and/or alcohol abuse at the time of enrolment; - Participant is currently, or planning to participate in another study during the study period; - Participant has a history of non-compliance; - Participant has taken antibiotics in the 12-weeks prior to randomisation.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Lactobacillus gasseri BNR17™ capsule
Once per day (QD), 12 weeks
Other:
Placebo capsule
Once per day (QD), 12 weeks

Locations

Country Name City State
Ireland Atlantia Food Clinical Trials Cork

Sponsors (1)

Lead Sponsor Collaborator
UAS Labs LLC

Country where clinical trial is conducted

Ireland, 

Outcome

Type Measure Description Time frame Safety issue
Other Gastrointestinal symptom rating scale 12 weeks
Other Safety blood profile (clinical chemistry and full blood count) 12 weeks
Other Vitals (systolic blood pressure, diastolic blood pressure, heart rate and temperature) 12 weeks
Other Adverse events (frequency, severity and relatedness) 12 weeks
Primary Absolute change from baseline to week 12 in visceral adipose tissue (VAT) VAT will be assessed using dual energy x-ray absorptiometry 12 weeks
Secondary Absolute change from baseline to week 12 in total fat mass 12 weeks
Secondary Absolute change from baseline to week 12 in total lean mass 12 weeks
Secondary Absolute change from baseline to week 12 in body weight 12 weeks
Secondary Absolute change from baseline to week 12 in waist circumference 12 weeks
Secondary Absolute change from baseline to week 12 in waist-to-hip ratio 12 weeks
Secondary Absolute change from baseline to week 12 in blood glucose 12 weeks
Secondary Absolute change from baseline to week 12 in HbA1c 12 weeks
Secondary Absolute change from baseline to week 12 in blood insulin 12 weeks
Secondary Absolute change from baseline to week 12 in hs-CRP 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT03360058 - Obesity and Type 2 Diabetes - Raising the Issue of Weight Management in Primary Care N/A
Active, not recruiting NCT05400187 - Body Composition Assessment and Smart-phone Based Counselling on Healthy Eating and Weight Management N/A
Completed NCT01731197 - Satiating Effects of Isolated Soy Proteins N/A
Recruiting NCT06147752 - Mobile Internet Healthcare and Three Disciplines Co-management Intervention for Overweight/Obese Prediabetic Patients N/A
Not yet recruiting NCT06428695 - Education Session to Improve Program Adherence N/A
Completed NCT06312917 - Effect of Physical Activity Intervention on Overweight and Obese Patients With Endometrial Cancer N/A
Completed NCT01575886 - Enhancing Teachable Moment Communication for Smoking Cessation and Weight Management N/A
Completed NCT01030354 - Effects of Protein-Enriched Meal on Liver, Kidney or Bone: a Randomized Controlled Trial Phase 2/Phase 3
Enrolling by invitation NCT01511393 - An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)
Completed NCT03872297 - Fish Collagen Peptide Food Supplement on Weight and Body Composition N/A
Recruiting NCT05257239 - Acceptability and User Perceptions of Artificial Intelligence-based Mobile Applications Adoption for Weight Management: A Sequential Explanatory Study
Completed NCT00542009 - A Trial In Diabetic Patients To Assess Effect Of CE-326,597 On Glucose Control And Body Weight Phase 2
Recruiting NCT05869604 - Healthy Lifestyles After Cancer for Adolescents and Young Adults: A Program to Reduce Cardiovascular Risk Factors N/A
Unknown status NCT00866151 - A to Z Study Follow-up: Collection of DNA Data From Buccal Swabs N/A
Active, not recruiting NCT05813795 - A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity Phase 3
Recruiting NCT05534386 - A Self-management Based Survivorship Intervention for Chinese Cancer Survivors N/A